FDA Approved Products
4,491 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
MENTAX
butenafine hydrochloride
LOE Approaching
TOPICAL · CREAM
1996
NDA30/100
MENTAX-TC
butenafine hydrochloride
LOE Approaching
TOPICAL · CREAM
2002
NDA30/100
MEPERGAN
meperidine hydrochloride; promethazine hydrochloride
LOE Approaching
Hikma
INJECTION · INJECTABLE
1961
NDA30/100
MEPHYTON
phytonadione
LOE Approaching
Bausch + Lomb
ORAL · TABLET
1955
NDA30/100
MEPROBAMATE
meprobamate
LOE Approaching
Molecular Devices
ORAL · TABLET
1963
NDA30/100
MEPROBAMATE
meprobamate
LOE Approaching
Novartis
ORAL · TABLET
1963
NDA30/100
MEPROBAMATE
meprobamate
LOE Approaching
ORAL · TABLET
1964
NDA30/100
MEPROBAMATE
meprobamate
LOE Approaching
ORAL · TABLET
1964
NDA30/100
MEPRON
atovaquone
LOE Approaching
GSK
ORAL · SUSPENSION
Pneumocystis jirovecii pneumonia (PCP) in adultsadolescents (aged 13 years+5
1995
NDA30/100
MEPRON
atovaquone
LOE Approaching
GSK
ORAL · TABLET
1992
NDA30/100
MERETEK UBT KIT (W/ PRANACTIN)
urea c-13
LOE Approaching
Otsuka
ORAL · FOR SOLUTION
1996
NDA30/100
MERIDIA
sibutramine hydrochloride
LOE Approaching
Abbott
ORAL · CAPSULE
1997
NDA30/100
MERREM IV
meropenem
LOE Approaching
Pfizer
INJECTION · INJECTABLE
1996
NDA30/100
MESANTOIN
mephenytoin
LOE Approaching
Novartis
ORAL · TABLET
1946
NDA30/100
MESNEX
mesna
LOE Approaching
Baxter
INTRAVENOUS · INJECTABLE
hematuria due to other pathological conditions such
1988
NDA30/100
MESNEX
mesna
LOE Approaching
Baxter
ORAL · TABLET
hematuria due to other pathological conditions such
2002
NDA30/100
MESTINON
pyridostigmine bromide
LOE Approaching
Bausch + Lomb
INJECTION · INJECTABLE
1955
NDA30/100
MESTINON
pyridostigmine bromide
LOE Approaching
Bausch + Lomb
ORAL · TABLET
1955
NDA30/100
MESTINON
pyridostigmine bromide
LOE Approaching
Bausch + Lomb
ORAL · SYRUP
1965
NDA30/100
MESTINON
pyridostigmine bromide
LOE Approaching
Bausch + Lomb
ORAL · TABLET, EXTENDED RELEASE
1959
NDA30/100
METADATE CD
methylphenidate hydrochloride
LOE Approaching
Aytu BioPharma
ORAL · CAPSULE, EXTENDED RELEASE
Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 to 15 years of age
2001
NDA30/100
METAGLIP
glipizide; metformin hydrochloride
LOE Approaching
Bristol Myers Squibb
ORAL · TABLET
2002
NDA30/100
METASTRON
strontium chloride sr-89
LOE Approaching
Q BioMed
INJECTION · INJECTABLE
1993
NDA30/100
METHADONE HYDROCHLORIDE
methadone hydrochloride
LOE Approaching
Hikma
ORAL · TABLET, FOR SUSPENSION
1973
NDA30/100